Overview
This is a Multi-center, Open-labe, Phase I/II Study to evaluate the safety and tolerability of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor.
Eligibility
Inclusion Criteria:
- Fully understand the study and voluntarily sign the informed consent form.
- Male or female 18-70 years of age;
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or
- Life expectancy ≥ 3 months.
Exclusion Criteria:
- Patients were deemed unsuitable for participating in the study by the investigator for any reasons.